University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
NCT Number: NCT01969370
This study is part of a larger consortium project investigating the validity and best use of next-generation sequencing (in particular, whole exome sequencing, or WES) in clinical care. This sub-project is investigating benefits and harms of providing WES diagnostic and different types of incidental findings to adult patients and parents of pediatric patients who undergo WES because they have symptoms suggesting genetic disease.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Chapel Hill, North Carolina, 27599, United States
This study is part of a larger consortium project investigating the validity and best use of next-generation sequencing (in particular, whole exome sequencing, or WES) in clinical care. Participants are patients who were either seen in the University of North Carolina Cancer and Adult Genetics Clinic or referred to the study by their physician. They will be approached by their physician or a genetic counselor for recruitment. Once enrolled, a clinical geneticist or genetic counselor will obtain consent and collect blood samples to be analyzed using WES. Results may include information related to a diagnosis and incidental information. Medically actionable incidental findings will be CLIA (Clinical Laboratory Improvement Amendments)-certified and returned to participants in a routine genetic counseling session, along with diagnostic findings. Eligible adult participants will be randomized to have the opportunity to choose to get certain types of non-medically actionable incidental findings, as well. Their decisions will be investigated, as will psychosocial and behavioral responses to sequencing and receiving sequencing information. This is a longitudinal, mixed methods study (i.e., multiple assessments pre- and post-return of results, with both quantitative and qualitative methods used to gather data). Because only the quantitative component of the study uses randomization, only measures and procedures associated with that component are described here.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Cancer
Cardiovascular Conditions
Pediatric neurodevelopmental disorders
Option to request non-medically actionable incidental information (after receiving education about them)
Time frame: 2 weeks after return of diagnostic results; for adult patient participants who are eligible and who request them, 2 weeks after return of non-medically actionable incidental results
Measured with an adapted version of the multidimensional impact of testing scale (MICRA)
Time frame: Adult patient participants: change from 2 weeks after return of diagnostic results to 3 months and 6 months after return of diagnostic results
Measure is an adapted version of the multidimensional impact of testing scale MICRA)
Time frame: 2 weeks after return of diagnostic results
Motivations of communications will also be assessed and examined for descriptive analyses.
Time frame: 2 weeks after consent (T1) and change from T1 to 2 weeks after return of diagnostic results
Participants will answer questions about the extent to which they sought information about whole exome sequencing and results it produces. Questions also ask about sources of that information (e.g., the Internet, doctors) to provide descriptive data about how participants get information.
Time frame: All participants: 2 wks after consent (T1)
Time frame: All participants: 2 wks after return of diagnostic (dx) results and, for eligible adults who request them, return of incidental results
Also administered 2 wks after return of non-medically actionable incidental results for eligible adult patient participants who request them.
Time frame: For all participants: Change from post-consent to post-return of results; Additional for adults: change at 3 and 6 months after return of dx results
Time frame: All participants: 2 wks after consent (T1)
Time frame: All participants: 22 wks after return of diagnostic (dx) results
Time frame: All participants: Change in utilization from post-consent to post-return of results; Additional for adult patients: Change at 3 and 6 months after return of dx results
Time frame: Adult participants: 2 wks after consent (T1)
Behaviors include those related to diet, physical activity, smoking, drinking, and substance use.
Time frame: Adult participants: 2 wks after return of diagnostic (dx) results
Behaviors include those related to diet, physical activity, smoking, drinking, and substance use.
Time frame: Adult participants: Change in behaviors from 2 wks after consent (T1) to 2 wks, 3 months, and 6 months after return of dx results
Behaviors include those related to diet, physical activity, smoking, drinking, and substance use.
Time frame: All participants: 2 wks after consent
Symptoms of depression and anxiety measured with the Hospital Anxiety and Depression Scale
Time frame: All participants: 2 wks after return of diagnostic (dx) results
Symptoms of depression and anxiety measured with the Hospital Anxiety and Depression Scale
Time frame: All participants: Change from 2 wks after consent (T1) to 2 wks after return of diagnostic (dx) results; Additional for adult patients: Change at 3 and 6 months after return of dx results
Symptoms of depression and anxiety measured with the Hospital Anxiety and Depression Scale
Time frame: All participants: 2 wks after consent (T1)
Measured with the Medical Outcomes Study Short Form-12
Time frame: All participants: 2 wks after return of diagnostic results
Measured with the Medical Outcomes Study Short Form-12
Time frame: All participants: Change from 2 wks after consent to 2 weeks after return of diagnostic results
Measured with the Medical Outcomes Study Short Form-12
University of North Carolina, Chapel Hill
Other
Acronym: NCGENES
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02553148
Cancer, Cardiovascular Disease
Fairfax Station, Virginia, United States
View Trial DetailsNCT02422745
Cancer, Cardiovascular Disease
Boston, Massachusetts, United States
View Trial DetailsNCT01633021
Anemia, Anemia, Hemolytic
Bethesda, Maryland, United States
View Trial DetailsNCT02742597
Alzheimer Disease, Alzheimer's Disease
London, Ontario, Canada
View Trial Details